IONIS-FB-LRx, also known as RG6299, is an investigational ligand-conjugated antisense (LICA) medicine designed to inhibit the production of complement factor B (FB), and the alternative complement pathway.
About IgA Nephropathy
Genetic association studies have shown that overaction of the alternative complement pathway has been associated with the development of several complement-mediated diseases, including immunoglobulin A, or IgA, nephropathy, or IgAN.
IgAN is one of the most common causes of inflammation that impairs the filtering ability of kidneys and is an important cause of chronic kidney disease and kidney failure. Also known as Berger’s disease, IgAN is characterized by deposits of IgA in the kidneys, resulting in inflammation and tissue damage.
Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.